Here are four things to know:
1. The company surpassed its goal of $1.5 million in the funding round.
2. The funding comes weeks before the company’s anticipated launch date for its magnesium-based bone void filler product, OsteoCrete.
3. OsteoCrete is resorbable, injectable, moldable, osteoconductive and nontoxic.
4. The FDA cleared the product for long-bone and general orthopedic applications.
More articles on devices:
Histogenics acquires sole development, marketing rights for NeoCart in Japan: 5 key notes
Study: Cartiva SCI an effective for toe osteoarthritis treatment — 4 points
Medtronic invests in Mazor, inks commercial agreement: 6 things to know
